1. Pink Sheet
  2. >>R&D

Handful Of Drugs Aim To Modify Osteoarthritis

 
• By Brenda Sandburg

Disease modifying treatments in Phase II target cartilage repair and regeneration. Sponsors are enthusiastic about FDA guidance offering to help sponsors with their programs.

PS1808_Osteoarthritiscovered_1030913119_1200.jpg

A new FDA draft guidance is casting a spotlight on a "Holy Grail" in drug development: disease-modifying treatments for osteoarthritis. While most osteoarthritis drugs in the pipeline are intended to treat pain and other symptoms, a handful seek to alter the underlying pathology and structural progression of the disease.

On Aug. 22, the agency issued a two-page guidance for sponsors developing drugs, devices or biological products for these claims. No products have been approved for treatment of structural progression...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from R&D

US FDA’s Prasad: ‘We Will Always Embrace Surrogate Endpoints’

 
• By Sarah Karlin-Smith

The new CBER director, once best known in the pharma world for criticizing accelerated approval, committed to expediting cancer drugs with surrogate endpoints.

UK And US Regulators In Sync On RWD External Control Arms

 
• By Vibha Sharma

The UK regulator’s draft guideline on the use of external control arms based on real-world data reflects concepts similar to those outlined by the US Food and Drug Administration.

EMA: ‘Sad To See’ Member States Against Patient Engagement Under EU Pharma Reform

 
• By Eliza Slawther

The European Medicines Agency’s chief medical officer Steffen Thistrup argued that patients are able to understand the “complex regulatory and scientific issues” that the EMA committees discuss when they assess drugs.

More from Pink Sheet

How Pharma Companies Can Mitigate The Impact Of US Tariffs On The Supply Chain

 
• By Ewan Townsend

If US tariffs on pharmaceutical supply chain products come into force they could be disruptive for companies. Ewan Townsend, of the international law firm Arnold & Porter, explains how companies can mitigate issues through negotiating with suppliers and reallocating tariff responsibilities.

‘The Question Is, What’s Going To Happen Next?’ – The Future For Biosimilars In Europe

 
• By Dave Wallace

With European biosimilars developers buoyed by recent regulatory moves, Medicines for Europe’s Isabell Remus and Julie Maréchal-Jamil discuss the next steps forward for the industry.